15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1)
Journal of Clinical Oncology · 2024-10 · 42 (28) · 3319-3329
DOI: 10.1200/jco.24.00447 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, 2024-10. Verfasst von J William Harbour und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX. Hauptthemen laut MEDLINE: Melanoma, Uveal Neoplasms, Antigens, Neoplasm, Gene Expression Profiling. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Validated and accurate prognostic testing is critical for precision medicine in uveal melanoma (UM). Our aims were to (1) prospectively validate an integrated prognostic classifier combining a 15-gene expression profile (15-GEP) and PRAME RNA expression and (2) identify clinical variables that enhance the prognostic accuracy of the 15-GEP/ PRAME classifier. MATERIALS AND METHODS This study included 1,577 patients with UM of the choroid and/or ciliary body who were enrolled in the Collaborative Ocular Oncology Group Study Number 2 (COOG2) and prospectively monitored across 26 North American centers. Test results for 15-GEP (class 1 or class 2) and PRAME expression status (negative or positive) were available for all patients. The primary end point was metastasis-free survival (MFS). RESULTS 15-GEP was class 1 in 1,082 (68.6%) and class 2 in 495 (31.4%) patients. PRAME status was negative in 1,106 (70.1%) and positive in 471 (29.9%) patients. Five-year MFS was 95.6% (95% CI, 93.9 to 97.4) for class 1/ PRAME (–), 80.6% (95% CI, 73.9 to 87.9) for class 1/ PRAME (+), 58.3% (95% CI, 51.1 to 66.4) for class 2/ PRAME (–), and 44.8% (95% CI, 37.9 to 52.8) for class 2/ PRAME (+). By multivariable Cox proportional hazards analysis, 15-GEP was the most important independent predictor of MFS (hazard ratio [HR], 5.95 [95% CI, 4.43 to 7.99]; P < .001), followed by PRAME status (HR, 1.82 [95% CI, 1.42 to 2.33]; P < .001). The only clinical variable demonstrating additional prognostic value was tumor diameter. CONCLUSION In the largest prospective multicenter prognostic biomarker study performed to date in UM to our knowledge, the COOG2 study validated the superior prognostic accuracy of the integrated 15-GEP/ PRAME classifier over 15-GEP alone and clinical prognostic variables. Tumor diameter was found to be the only clinical variable to provide additional prognostic information. This prognostic classifier provides an advanced resource for risk-adjusted metastatic surveillance and adjuvant trial stratification in patients with UM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX.
- Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.
- Bascom Palmer Eye Institute and Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL.
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL.
- Retina Consultants of Texas, Houston, TX.
- Byers Eye Institute, Department of Ophthalmology, Stanford University, Stanford, CA.
ORCID-Profile: J William Harbour, Zelia M Correa, Prithvi Mruthyunjaya, Ezekiel Weis, Ivana K Kim, Timothy S Fuller, Basil K Williams, Eugene Shildkrot, Scott C Oliver, Michael Altaweel, Tony Tsai, Christina L Decatur, James J Dollar, Song Zhang
Förderung
- NEI NIH HHS
- NCI NIH HHS
Zitieren
APA
Harbour, J. W., Correa, Z. M., Schefler, A. C., Mruthyunjaya, P., Materin, M. A., Aaberg, T. A., Skalet, A. H., Reichstein, D. A., Weis, E., Kim, I. K., Fuller, T. S., Demirci, H., Piggott, K. D., Williams, B. K., Shildkrot, E., Capone, A., Oliver, S. C., Walter, S. D., Mason, J., …, & Zhang, S. (2024). 15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1). Journal of Clinical Oncology, 42(28), 3319-3329. https://doi.org/10.1200/jco.24.00447
Vancouver
Harbour JW, Correa ZM, Schefler AC, Mruthyunjaya P, Materin MA, Aaberg TA, et al. 15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1). Journal of Clinical Oncology. 2024;42(28):3319-3329. doi:10.1200/jco.24.00447
BibTeX
@article{Harbour2024,
author = {Harbour, J William and Correa, Zelia M and Schefler, Amy C and Mruthyunjaya, Prithvi and Materin, Miguel A and Aaberg, Thomas A and Skalet, Alison H and Reichstein, David A and Weis, Ezekiel and Kim, Ivana K and Fuller, Timothy S and Demirci, Hakan and Piggott, Kisha D and Williams, Basil K and Shildkrot, Eugene and Capone, Antonio and Oliver, Scott C and Walter, Scott D and Mason, John and Char, Devron H and Altaweel, Michael and Wells, Jill R and Duker, Jay S and Hovland, Peter G and Gombos, Dan S and Tsai, Tony and Javid, Cameron and Marr, Brian P and Gao, Ang and Decatur, Christina L and Dollar, James J and Kurtenbach, Stefan and Zhang, Song},
title = {15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1)},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {28},
pages = {3319--3329},
doi = {10.1200/jco.24.00447}
}
EUVIMED